OnKure Therapeutics nabs $60M as HDAC inhibitorHDAC inhibitor awaits solid-tumor readouts

04 Apr 2023
endpts.com
Phase 2PROTACs
OnKure Therapeutics has lined up $60 million in a new private funding round, adding to the Boulder, CO, biotech’s bank account as it works through a Phase II trial.
The startup is attempting to create an inhibitor of histone deacetylases, or HDACs, which are DNA-manipulating enzymes that alter how genes get expressed. They’ve been a cancer target for decades, with about half a dozen FDA approvals for the class, but treatment nods so far have focused on blood cancers. That includes the drugs Zolinza, Istodax, Beleodaq, Epidaza and Farydak.
OnKure Therapeutics nabs $60M as HDAC inhibitor awaits solid-tumor readouts
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 164,200+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.